Akin Gump·FDA / LIFE SCIENCES REGULATORY

FDA Proposes PDUFA VIII Commitment Letter for FY2028-2032

The FDA's proposed PDUFA VIII commitment letter sets performance goals and timelines for human drug review through 2032, with public comment open until October 16, 2026, and Congressional submission due January 15, 2027.

pdufa-reauthorizationfda-drug-reviewuser-fee-programpharmaceutical-regulationcongress-actionclinical-trials
Read the original firm alert → Thursday, August 27, 2026

Stay ahead

Join the digest.

One email when the daily AmLaw 100 briefing ships. No noise, no pitch decks — just the grade 4–5 signal.